Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease  
Following on from information provided to NICE by the company in June 2018, the appraisal of Atherothrombotic events - vorapaxar was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 616
Referral date 01 November 2014

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: 01 January 2100

Project Team

Associate Director: TBC
Communications manager: TBC
Project manager:

TBC

Technical Advisor: TBC
Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 November 2022 Discontinued. Following on from information provided to NICE by the company in June 2018, the appraisal of Atherothrombotic events - vorapaxar was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
19 December 2014

Please note that following on from information received from the company, this appraisal will be rescheduled to align with the commercial availability of the product within the UK. Therefore, NICE has decided to suspend this appraisal from its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.


For further information on our processes and methods, please see our CHTE processes and methods manual